Patents by Inventor Theresa Branchek

Theresa Branchek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7132248
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: November 7, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Patent number: 7067277
    Abstract: This invention provides isolated nucleic acids encoding chimeric G proteins, vectors comprising nucleic acids encoding chimeric G proteins, cells comprising such vectors, processes of determining agonists and antagonists of mammalian G protein-coupled receptors utilizing chimeric G proteins, processes of determining compounds which bind to mammalian G protein-coupled receptors utilizing chimeric G proteins, processes for making a composition of matter which specifically binds to a mammalian G protein-coupled receptor utilizing chimeric G proteins, processes for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by a process of the invention utilizing chimeric G proteins, processes of identifying a ligand for a mammalian G protein-coupled receptor utilizing chimeric G proteins, and processes of screening a plurality of independent clones to identify and isolate a clone encoding a mammalian G protein-coupled receptor utilizing chi
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: June 27, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Kenneth A. Jones, Mary W. Walker, Joseph Tamm, Theresa A. Branchek, Christophe P. G. Gerald
  • Patent number: 7060449
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: June 13, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 7022489
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: April 4, 2006
    Assignee: H. Lundbeck A/S
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
  • Publication number: 20060014242
    Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.
    Type: Application
    Filed: November 12, 2004
    Publication date: January 19, 2006
    Inventors: Christophe Gerald, Richard Weinshank, Mary Walker, Theresa Branchek
  • Patent number: 6913892
    Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: July 5, 2005
    Assignee: H. Lundbeck A/S
    Inventors: Jonathan A. Bard, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
  • Patent number: 6818445
    Abstract: This invention provides isolated nucleic acid molecules encoding a neuropeptide Y (NPY) Y5 receptor which hybridizes under high stringency conditions to a nucleic acid molecule of SEQ ID NO:3, vectors comprising such isolated nucleic acid molecules, and cells comprising such vectors.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: November 16, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
  • Patent number: 6790656
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: September 14, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 6713265
    Abstract: The invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has structure (I). In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: March 30, 2004
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
  • Publication number: 20030215823
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: October 31, 2002
    Publication date: November 20, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Patent number: 6645774
    Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: November 11, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
  • Publication number: 20030166066
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian 5-HT4B receptor and an isolated nucleic acid encoding a human 5-HT4B receptor, an isolated protein which is a mammalian 5-HT4B receptor, vectors comprising an isolated nucleic acid encoding a mammalian 5-HT4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid which encodes a mammalian or human 5-HT4B receptor, and pharmaceutical compounds related to the human 5-HT4B receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT4B receptor.
    Type: Application
    Filed: April 9, 2002
    Publication date: September 4, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Theresa Branchek, Richard L. Weinshank
  • Publication number: 20030162944
    Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.
    Type: Application
    Filed: July 2, 2002
    Publication date: August 28, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Christophe Gerald, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
  • Patent number: 6602888
    Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: August 5, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
  • Publication number: 20030129702
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P.G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 6586191
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: July 1, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
  • Publication number: 20030082641
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: January 26, 2001
    Publication date: May 1, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
  • Publication number: 20030082672
    Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: July 23, 1997
    Publication date: May 1, 2003
    Inventors: KELLI E. SMITH, DAVID LINEMEYER, CHRISTOPHE GERALD, THERESA BRANCHEK, RICHARD L. WEINSHANK, CARLOS FORRAY
  • Publication number: 20030027254
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
    Type: Application
    Filed: December 3, 2001
    Publication date: February 6, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
  • Publication number: 20030022900
    Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.
    Type: Application
    Filed: June 28, 2002
    Publication date: January 30, 2003
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig